Luin, M. van

patient plasma concentration efavirenz group dose reduction study hiv-infected antiretroviral reduction hiv-infected patients atovaquone /ritonavir response raltegravir therapy lopinavir /ritonavir baseline efv plasma concentrations pneumococcal cancer effect vaccine level efv plasma concentration serotype disease virus william rd group department atazanavir /ritonavir virological lippincott wilkin discontinuation lopinavir treatment vaccination virological response incidence atazanavir hospital nijmegen population antibody darunavir plasma concentrations pharmacokinetic haemodialysi university status proguanil inhibitor ritonavir article lung cancer pretreated status cohort reproduction /proguanil infection hiv infection copyright radboud university nijmegen netherland toxicity-induced women efv plasma exposure medicine speci fic antibodies etravirine france cyp 2b efv dose interval exposure toxicity lopinavir / ritonavir 8 weeks